Table 3 Summary of patients in remission at month 12 stratified by previous treatment and entry route (efficacy population; n = 451)
Treatment in parent studiesEntry route into maintenance phasePatients in remission at the end of 12 months, n (%)
MMX mesalazine 2.4 g/dayTotal
2.4 g given once daily (n = 225)1.2 g given twice daily (n = 234)
PlaceboDirect18/22 (81.8)16/20 (80.0)34/42 (81.0)
Via 8-week extension19/34 (55.9)25/41 (61.0)44/75 (58.7)
MMX mesalazine 2.4 g/day*Direct25/37 (67.6)33/42 (78.6)58/79 (73.4)
Via 8-week extension14/29 (48.3)13/24 (54.2)27/53 (50.9)
MMX mesalamine 4.8 g/dayDirect30/42 (71.4)32/41 (78.0)62/83 (74.7)
Via 8-week extension15/27 (55.6)17/28 (60.7)32/55 (58.2)
Asacol 2.4 g/day†Direct15/17 (88.2)13/19 (68.4)28/36 (77.8)
Via 8-week extension5/11 (45.5)10/17 (58.8)15/28 (53.6)
  • *Patients received MMX mesalazine 2.4 g/day given once daily in the Kamm study,25 and as 1.2 g twice daily in the Lichtenstein study.24 †Patients received Asacol 2.4 g/day (given as 0.8 g three times daily) as a reference arm in study 302 only.